| Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (NCT05150457) | Binacea Pharma, Inc. | 2022-02-08 |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation (NCT04869475) | Ruijin Hospital | 2021-04-20 |
| A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) (NCT04718675) | Kronos Bio | 2021-02-08 |
| MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors (NCT06030869) | Tianjin Medical University Second Hospital | 2020-12-01 |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors (NCT03810742) | PharmaEngine | 2019-03-05 |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors (NCT03739827) | National Cancer Institute (NCI) | 2019-01-28 |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (NCT03247309) | Immatics US, Inc. | 2018-12-19 |
| Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors (NCT02691793) | Samsung Medical Center | 2017-11-20 |
| A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (NCT03052205) | Idera Pharmaceuticals, Inc. | 2017-06-09 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer (NCT03096340) | Intezyne Technologies, Inc. | 2017-03-23 |
| Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors (NCT02688881) | Samsung Medical Center | 2017-02-05 |
| Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors (NCT02691780) | Samsung Medical Center | 2016-12-23 |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors (NCT02450149) | Samsung Medical Center | 2016-05-30 |
| Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors (NCT02691767) | Samsung Medical Center | 2016-05-01 |
| Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors (NCT02450123) | Samsung Medical Center | 2016-03-23 |
| A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (NCT02596503) | University of Colorado, Denver | 2015-10-21 |
| Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors (NCT02450136) | Samsung Medical Center | 2015-10-08 |
| A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (NCT02482441) | OncoMed Pharmaceuticals, Inc. | 2015-07-16 |
| A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma (NCT02383368) | Astellas Pharma Global Development, Inc. | 2015-03-23 |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval (NCT01525394) | Eisai Inc. | 2010-12-01 |
| An Open-Label, Dose-Escalation Study of AZD2461 (NCT01247168) | AstraZeneca | 2010-11-01 |
| Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment (NCT00914914) | Dr. Tapas K. Das Gupta | 2009-04-01 |
| A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors (NCT00923728) | Vertex Pharmaceuticals Incorporated | 2009-04-01 |
| PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors (NCT00759928) | SCRI Development Innovations, LLC | 2008-10-01 |
| Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia (NCT00665990) | St. Jude Children's Research Hospital | 2007-11-01 |
| A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors (NCT00664586) | Erimos Pharmaceuticals | 2007-05-01 |
| A Phase I/Expansion Study of Dasatinib (NCT00598091) | Duke University | 2007-04-01 |
| A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors (NCT00404508) | National Institute of Cancerología | 2005-09-01 |
| Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors (NCT00394446) | Myrexis Inc. | 2005-03-01 |